Hodgkin lymphoma tagged posts

Combination Immunotherapy shows high activity against recurrent Hodgkin lymphoma

Brentuximab vedotin mechanism of action.

Brentuximab vedotin mechanism of action.

A new combination of three drugs that harness the body’s immune system is safe and effective, destroying most cancer cells in 95% of patients with recurrent Hodgkin lymphoma, according to the results of an early-phase study.

Presented Dec. 3 at the annual meeting of the American Society of Hematology in San Diego, the study in 19 men and women found that injections of ipilimumab (marketed as Yervoy), nivolumab (Opdivo), and brentuximab vedotin (ADCETRIS) safely decreased tumor size or spread to some degree in 18 patients after at least six months of treatment, with 16 patients showing complete disappearance (remission) of tumors. After nine months of treatment, 15 remained in complete remission with no sign of their cancer’s return (relapse).

Resear...

Read More